CD4 and neoplasm: In the tumor, however, SAR131675 treatment decreased CD8+ T cells’ frequency compared to CD4 and to a lesser extent DNT (Table 2, Supplementary Table S3), while there was no effect on the relative frequency of activated PD1+ T cell subsets.